9 June 2026 in The Journal of Heart and Lung Transplantation
The Organ Procurement and Transplantation Network (OPTN) Standard Transplant Analysis and Research (STAR) files are commonly used to study use of mechanical circulatory support (MCS) among heart transplant candidates. However, the STAR MCS file reports devices only for candidates removed from the waitlist, whereas the Scientific Registry of Transplant Recipients (SRTR) MCS file includes devices for all candidates. We compared the STAR and SRTR MCS files in estimating trends in LVAD support and waitlist outcomes among heart transplant candidates with durable LVADs. We identified adult heart transplant candidates who obtained durable LVADs between October 18, 2018 and December 31, 2024 using MCS files from STAR (N=4,182) and SRTR (N=4,919). We estimated the cumulative incidence of transplantation and death/deterioration in both cohorts and analyzed LVAD prevalence at bimonthly intervals from October 2018 to April 2025. The SRTR cohort showed stable LVAD prevalence (30.7%-37.4%). In contrast, the STAR cohort constructed from the MCS file showed a 92.5% decline in LVAD prevalence (1,740 to 131 candidates), despite 971 candidates listed with status 4 for LVAD support on April 30, 2025. The STAR cohort demonstrated higher 3-year cumulative incidence of transplantation (66.7% vs 54.4%) and death/deterioration (10.1% vs 4.5%) after LVAD implantation. When we reran STAR-based analyses with both MCS and status justification files, prevalence and outcomes matched SRTR estimates. The STAR MCS file excludes LVADs among currently listed candidates, producing artifactual declines in LVAD prevalence and incidence and inflated waitlist outcomes. Awareness of registry construction is essential for accurate interpretation of LVAD-related outcomes.
22 June 2026 in Circulation: Heart Failure
BACKGROUND: In the US heart allocation system, when transplant centers submit applications for status exceptions to increase waitlist priority, patients obtain the requested status upgrades immediately while their applications are sent to the regional review boards (RRBs) and reviewed retrospectively. How often transplants occur during this period is unknown. METHODS: Using the Scientific Registry of Transplant Recipients, we identified all adult heart transplant candidates listed between October 18, 2018, and May 31, 2025, with submitted applications for status exceptions. We assessed (1) the time elapsed between submission of exception applications and their receipt by the RRBs and (2) the rate of heart transplantation during this travel time, stratified by whether the applications were eventually approved or denied. Additionally, we estimated how many listed patients were skipped by candidates who received transplants with exceptions that were ultimately denied. RESULTS: 138 transplant centers submitted status exception requests on behalf of 11 508 adult candidates during the study period, of whom 913 (7.9%) received a denial at least once. The median time from obtaining status upgrades to application receipt by the RRBs was 3 days. Three thousand seven out of 11 508 (26.1%) patients received transplants before the RRBs even received their applications, with 174 (19.1%) among 913 with eventual denials and 2833 (26.7%) among 10 595 with approvals. The cumulative incidence of heart transplantation before application receipt for eventual denials was 19.1% (95% CI, 16.6%–21.7%), and that for approvals was 27.2% (95% CI, 26.4%–28.0%; P <0.001) at 2 weeks. Candidates who received transplants despite being denied exceptions bypassed more than 11 thousand potential transplant recipients. CONCLUSIONS: More than 25% of patients with status exception requests receive heart transplants before their applications are even received by their RRBs, raising significant concerns about the fairness of retrospective review of exception requests for the allocation of donor hearts.
14 August 2026 in Clinical Transplantation
28 February 2026 in American Journal of Transplantation
23 June 2026 in Circulation: Heart Failure
BACKGROUND: The 2018 heart allocation policy change substantially lowered the priority of candidates supported with durable left ventricular assist devices (LVADs) for heart transplantation. To provide stable candidates supported by durable LVADs with a quicker path to transplantation before they suffer complications, the Organ Procurement and Transplantation Network (OPTN) approved a policy stipulating that stable patients supported by durable LVADs for 6 and 8 years will obtain statuses 3 and 2, respectively. METHODS: Using OPTN data, we identified all adult heart transplant candidates with a durable LVAD implanted between October 18, 2018 and May 31, 2025. We estimated the cumulative incidence of LVAD-related complications, treating transplantation and waitlist removal before experiencing complications as competing events. Furthermore, we assessed how the OPTN policy change would impact the status distribution of the waitlist. RESULTS: In our study cohort, 4967 adult patients who were listed for heart transplant received a durable LVAD. Transplant centers submitted 2879 justifications for status upgrades due to LVAD-related complications for 1812 (36.5%) patients. At 6 years after durable LVAD implantation, the cumulative incidence of complications and status upgrades was 42.1% (95% CI, 40.5%–43.8%), and that of transplantation was 36.0% (95% CI, 34.6%–37.6%). Of the 3779 patients who were not censored administratively, only 47 (1.2%) remained on the waitlist by 6 years after durable LVAD implantation. Had the 6- to 8-year OPTN policy change been implemented on June 1, 2025, only 4.7% of the waitlist would have changed statuses instantaneously. CONCLUSIONS: Almost all listed candidates with durable LVADs either experience a complication, status upgrade or are removed from the waitlist within 6 years of obtaining a durable LVAD. The upcoming OPTN policy is unlikely to prevent device complications before granting status upgrades and will likely impact a small percentage of candidates with durable LVADs.
15 September 2025 in medRxiv
Background: In the United States heart allocation system, when transplant centers submit applications for status exceptions to increase waitlist priority, patients obtain the requested status upgrades immediately while their applications are sent to the regional review boards (RRBs) and reviewed retrospectively. How much time elapses between obtaining a status upgrade through exception and application receipt by the RRBs and how often transplants occur during this period is unknown. Methods: Using the Scientific Registry of Transplant Recipients (SRTR), we identified all adult heart transplant candidates listed between October 18, 2018 and December 31, 2023 with submitted applications for status exceptions. We assessed 1) the amount of time elapsed between submission of exception applications and their receipt by the RRBs and 2) the rate of heart transplantation during this “travel” time, stratified by whether the applications were eventually approved or denied. Additionally, using complete match run data, we estimated how many listed patients were skipped by candidates who received transplants with exceptions that were ultimately denied. Results: 135 transplant centers submitted status exception requests on behalf of 8,269 adult candidates during the study period, of whom 608 (7.4%) received a denial at least once. The median time from obtaining higher priority statuses immediately via exceptions to application receipt by the RRBs was 3 days. 2,087 out of 8,269 (25.2%) patients received transplants before the RRBs even received their applications, with 115 (18.9%) among 608 with eventual denials and 1,972 (25.7%) among 7,661 with approvals. The cumulative incidence of heart transplantation before application receipt for eventual denials was 19.1% (95% CI [16.0%, 22.3%]) and that for approvals was 26.2% (95% CI [25.2%, 27.1%]) (p < 0.001) at 2 weeks. Based on match run data, the 115 patients who received transplants with denied exceptions bypassed more than seven thousand potential transplant recipients. Conclusions: More than 25% of patients with status exception requests receive heart transplants before their applications are even received by their respective RRBs, let alone reviewed. This raises significant concerns about the efficacy and fairness of retrospective review of exception requests for the allocation of valuable donor hearts.